We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Non-Invasive Skin Biopsy Test Allows Clinicians to Look inside Nerves for Diagnosing Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 24 Mar 2023

The diagnosis of neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy can pose significant challenges for clinicians. More...

According to scientific studies, these disorders are misdiagnosed over 30% of the time, particularly during the early stages of presentation. Over the years, researchers have searched for biomarkers in the blood and spinal fluid and employed advanced radiographic methods to image neuron changes in the brain. However, these tests have not been sufficiently sensitive or specific, often failing to detect individuals with the diseases or indicating disease consistency in those who do not have them.

CND Life Sciences (Phoenix, AZ, USA) has developed the first-ever test in the market that can examine the nerves inside the human body and detect the protein accumulation in individuals with synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder. These diseases are characterized by the accumulation of a misfolded protein called alpha-synuclein in the nervous system, which is unique to individuals with synucleinopathies.

The Syn-One Test is a minimally invasive skin biopsy (a punch biopsy with no stitches required) that provides physicians with visual evidence of these proteins accumulating within a patient’s nerves. Skin punch biopsy is an effective, reliable, non-invasive test for detecting such proteins, and can help find a cure for these neurodegenerative diseases. The reliability and effectiveness of this minimally invasive test have gained the attention of hundreds of clinicians across the US who are now using it as a diagnostic aid for the early detection of these synucleinopathies.

"Syn-One is changing the way clinicians diagnose many of these complex neurodegenerative diseases, and in parallel, biopharmaceutical companies are realizing how important it is to use Syn-One as a biomarker for clinical trials targeting alpha-synuclein," said Todd Levine, MD, CND's Chief Medical Officer and Co-Founder.

Related Links:
CND Life Sciences 


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.